How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

Daratumumab monotherapy may help prevent progression to active myeloma in patients with smoldering disease. New research findings are summarized in a short video.

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti- multiple myeloma (MM ...

The recommended maintenance dosage is 100mg administered subcutaneously at week 16 ... the EC approved an extended indication for Janssen-Cilag International's Darzalex (daratumumab) subcutaneous ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that ...

This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab. The daratumumab DRP ® was developed by correlating gene expression patterns with ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...

This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab. The daratumumab DRP® was developed by correlating gene expression patterns with ...